Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.

The S&P/ASX 200 Index (ASX: XJO) surged higher this Thursday, soaring up a welcome 1.38% to finish at a flat 8,327 points.

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

The ASX200 closed down 0.22% at 8,213 points. The local bourse gave up early gains and slipped into the red in afternoon ...

These shares are having a tough time on hump day. But why? The post Why CAR Group, Myer, Neuren, and Yancoal shares are falling today appeared first on The Motley Fool Australia.

ASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) is having an awful day, down around 9%. Here's the tea.

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...